A detailed history of China Universal Asset Management Co., Ltd. transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 11,694 shares of PLRX stock, worth $155,530. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,694
Previous 7,087 65.01%
Holding current value
$155,530
Previous $76,000 72.37%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$10.52 - $14.35 $48,465 - $66,110
4,607 Added 65.01%
11,694 $131,000
Q2 2024

Jul 19, 2024

SELL
$10.58 - $15.61 $47,546 - $70,151
-4,494 Reduced 38.8%
7,087 $76,000
Q1 2024

Apr 29, 2024

BUY
$14.14 - $19.59 $65,779 - $91,132
4,652 Added 67.14%
11,581 $173,000
Q4 2023

May 21, 2024

SELL
$12.85 - $19.15 $59,778 - $89,085
-4,652 Reduced 40.17%
6,929 $125,000
Q4 2023

Jan 23, 2024

BUY
$12.85 - $19.15 $69,390 - $103,409
5,400 Added 353.17%
6,929 $125,000
Q3 2023

May 21, 2024

BUY
$14.58 - $20.15 $10,993 - $15,193
754 Added 97.29%
1,529 $26,000
Q3 2023

Oct 30, 2023

BUY
$14.58 - $20.15 $10,993 - $15,193
754 Added 97.29%
1,529 $27,000
Q2 2023

May 21, 2024

BUY
$18.12 - $30.56 $36 - $61
2 Added 0.26%
775 $14,000
Q2 2023

Jul 27, 2023

BUY
$18.12 - $30.56 $36 - $61
2 Added 0.26%
775 $14,000
Q1 2023

May 21, 2024

BUY
$18.73 - $36.26 $5,206 - $10,080
278 Added 56.16%
773 $20,000
Q1 2023

Apr 27, 2023

BUY
$18.73 - $36.26 $5,206 - $10,080
278 Added 56.16%
773 $21,000
Q4 2022

May 21, 2024

SELL
$17.0 - $25.43 $188,462 - $281,916
-11,086 Reduced 95.73%
495 $9,000
Q4 2022

Jan 31, 2023

BUY
$17.0 - $25.43 $663 - $991
39 Added 8.55%
495 $10,000
Q3 2022

Oct 21, 2022

BUY
$7.67 - $24.23 $3,497 - $11,048
456 New
456 $10,000

Others Institutions Holding PLRX

About PLIANT THERAPEUTICS, INC.


  • Ticker PLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,682,000
  • Market Cap $647M
  • Description
  • Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...
More about PLRX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.